Chronic Periodontitis
Conditions
Brief summary
Alendronate (ALN), commonly use bisphosphonates is proposed to have osteostimulative properties in vivo and in vitro, as shown by an increase in the matrix formation, and acts as a potent inhibitor of bone resorption. AV widely known for its wound healing, analgesic, antioxidant, antibacterial, antiviral, antifungal, immune boosting and significant anti-inflammatory properties. The present study aims to explore the efficacy of 1% ALN and AV gel as a local drug delivery as an adjunct to scaling and root planing (SRP) for the treatment of degree II furcation defects
Detailed description
Alendronate (ALN), commonly use bisphosphonates is proposed to have osteostimulative properties in vivo and in vitro, as shown by an increase in the matrix formation, and acts as a potent inhibitor of bone resorption. AV widely known for its wound healing, analgesic, antioxidant, antibacterial, antiviral, antifungal, immune boosting and significant anti-inflammatory properties. The present study aims to explore the efficacy of 1% ALN and AV gel as a local drug delivery as an adjunct to scaling and root planing (SRP) for the treatment of degree II furcation defects. Methods: Ninety patients with mandibular buccal class II furcation defects were randomly allocated into three treatment groups: SRP plus placebo gel (group 1), SRP plus 1% ALN gel (group 2) and SRP plus AV gel (group3). Clinical and radiographic parameters were recorded at baseline and gel were delivered at respective site. Then again all clinical and radiographic parameters were recorded after 6 and 12 months from baseline.
Interventions
DRUGplacebo
Oral prophylaxis followed by placement of placebo gel
DRUGAlendronate
Oral prophylaxis followed by placement of Alendronate gel
DRUGAloe Vera
Oral prophylaxis followed by placement of Aloe Vera gel
Sponsors
Government Dental College and Research Institute, Bangalore
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
25 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
Systemically healthy patients with mandibular class II furcation defects and asymptomatic endodontically vital mandibular molars with radiolucency in furcation area with PD ≥ 5mm and horizontal PD ≥ 3mm and with no history of antibiotic or any periodontal therapy in past 6 months were included in the study -
Exclusion criteria
Subjects with any known systemic disease, allergic to alendronate or aloe vera, on systemic alendronate therapy, alcoholics, tobacco users, pregnant or lactating women \-
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Bone defect depth | baseline, 6 & 12 months | Assessed in percentage |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in modified sulcus bleeding index | baseline, 6 & 12 months | scale 0-3 |
| Change in Plaque index | baseline, 6 & 12 months | scale 0-3 |
| Change in pocket probing depth | baseline, 6 & 12 months | measured in mm |
| Change in relative vertical clinical attachment level | baseline, 6 & 12 months | measured in mm |
| Change in relative horizontal clinical attachment level | baseline, 6 & 12 months | measured in mm |
Outcome results
None listed